Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.51 |
| ▸ | BTK | Q06187 | 9/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921697 | 0.88 | BTK (0.45) | BTKLCKEGFR | |
| SCHEMBL1921898 | 0.85 | KDM4C (0.49) | MAPK14BTKLCKEGFRAXL | |
| SCHEMBL1921495 | 0.84 | BTK (0.53) | MAPK14MAPK11BTKLCKEGFR | |
| SCHEMBL19149800 | 0.76 | BTK (0.60) | BTKLCKEGFRLYN | |
| SCHEMBL19149799 | 0.76 | BTK (0.60) | BTKLCKEGFRLYN | |
| SCHEMBL21330693 | 0.74 | BTK (0.64) | BTKLCKEGFRLYN | |
| SCHEMBL21330691 | 0.74 | BTK (0.64) | BTKLCKEGFRLYN | |
| SCHEMBL31302867 | 0.74 | BTK (0.64) | BTKLCKEGFRLYN | |
| SCHEMBL1922019 | 0.74 | EGFR (0.45) | BTKLCKEGFRLYN | |
| SCHEMBL3246734 | 0.73 | BTK (0.45) | BTKLCKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | claimed |
| US-20140107150-A1 | New Compounds II | PROXIMAGEN LTD (GB) | 2014-04-17 | — | — | US | claimed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | claimed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| EP-2328895-A1 | NEW COMPOUNDS II | Proximagen Limited (GB) | 2011-06-08 | — | — | EP | claimed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | claimed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | UPSHER-SMITH LABORATORIES, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | PROXIMAGEN LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| EP-2328895-B1 | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110195992-A1 | NEW COMPOUNDS II | PROXIMAGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2328895-A1 | NEW COMPOUNDS II | Proximagen Limited (GB) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031791-A1 | NEW COMPOUNDS II | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | MAPK14 3676/4885MAPK11 2718/4885MAPK13 4032/4885 |
| US-20160113893-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, AOX1 | MAPK14 4582/4885MAPK11 4307/4885MAPK13 4585/4885 |
| US-20110195992-A1 | NEW COMPOUNDS II | SSB, NFKBIA, ALOX15B | MAPK14 3464/4885MAPK11 2156/4885MAPK13 3491/4885 |
| US-20140107150-A1 | New Compounds II | SSB, NFKBIA, ALOX15B | MAPK14 3464/4885MAPK11 2156/4885MAPK13 3491/4885 |
| US-20160101072-A1 | Therapeutic uses of enzyme inhibitors | VAPB, VAPA, AOX1 | MAPK14 4744/4885MAPK11 4447/4885MAPK13 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.